10-Q: Cosmos Health Reports Strong Revenue Growth Amidst Rising Losses

Cosmos Health Inc. reported a significant increase in revenue for Q3 and the nine months ended September 30, 2025, driven by strategic expansions and acquisitions, though net losses widened due to substantial non-cash charges and increased financing costs.

Summary

• Revenue for the three months ended September 30, 2025, increased by 37.8% to $17,110,425, up from $12,411,048 in the prior year.
• Nine-month revenue grew by 13.4% to $45,568,655, compared to $40,202,238 in the same period of 2024.
• Gross profit for Q3 2025 surged by 115.6% to $2,602,618, and by 75.9% to $5,816,231 for the nine-month period, primarily due to higher sales volumes and a favorable shift towards higher-margin nutraceuticals and contract manufacturing.
• Net loss for Q3 2025 increased to $5,352,890 from $2,182,534 in Q3 2024, largely due to new non-cash charges related to convertible notes and derivative liabilities.
• The nine-month net loss also widened to $8,999,055 from $6,639,935 in 2024, influenced by the same non-cash valuation adjustments and higher interest expense.
• Cash and restricted cash significantly increased to $4,633,660 as of September 30, 2025, from $315,105 at December 31, 2024, primarily from financing activities.
• The company had negative working capital of $430,029 and an accumulated deficit of $123,021,330 as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, though management has secured significant financing and plans operational improvements.
• Cosmos Health regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price of $1.00) on October 16, 2025.

Sentiment

Score: 4

Explanation: While the company demonstrates strong revenue growth and strategic initiatives, the significant increase in net losses driven by non-cash charges, persistent negative operating cash flow, and the explicit 'going concern' warning indicate substantial financial challenges. The successful capital raises and Nasdaq compliance are positive, but the underlying profitability and internal control issues warrant caution.

Positives

• Revenue increased by 37.8% for the three months and 13.4% for the nine months ended September 30, 2025, driven by subsidiary growth and market expansion.
• Gross profit saw a substantial increase of 115.6% for Q3 and 75.9% for the nine-month period, reflecting improved sales mix with higher-margin products.
• Cash and restricted cash significantly improved to $4,633,660 as of September 30, 2025, from $315,105 at December 31, 2024, largely due to successful financing activities.
• Net cash provided by financing activities increased to $9,357,403 for the nine months ended September 30, 2025, from $3,426,621 in the prior year.
• The company secured a Securities Purchase Agreement for up to $300 million in senior secured convertible promissory notes, with an initial $8 million closing completed.
• Resumption of At-the-Market (ATM) sales program generated gross proceeds of $4,376,622 from September 22, 2025, to the filing date, further enhancing liquidity.
• Strategic expansions include the exclusive distribution of Sky Premium Life products in the UAE, with significant purchase orders already received.
• Cana S.A., the manufacturing subsidiary, is demonstrating improved revenue and gross profit and plans to strengthen contract manufacturing agreements.
• Cosmofarm S.A. expanded its client portfolio by approximately 75 new pharmacies during the period, driving wholesale revenue growth.
• The company regained compliance with Nasdaq's minimum bid price rule on October 16, 2025.

Negatives

• Net loss for the three months ended September 30, 2025, increased by 145% to $5,352,890, compared to $2,182,534 in the prior year.
• Nine-month net loss increased by 35.5% to $8,999,055, up from $6,639,935 in 2024.
• Operating activities continued to result in negative cash flow, with $3,851,273 used in operations for the nine months ended September 30, 2025.
• Total other income (expense), net, swung to a loss of $3,534,175 for Q3 2025, primarily due to new non-cash financial items.
• Significant non-cash charges include a $2.18 million change in fair value of convertible notes and a $0.31 million change in fair value of derivative liabilities for Q3 2025.
• Interest expense increased substantially to $669,150 in Q3 2025 and $1,245,071 for the nine-month period, driven by new financing arrangements and convertible notes.
• The company had negative working capital of $430,029 and an accumulated deficit of $123,021,330 as of September 30, 2025.
• Stockholders' equity decreased to $23,134,884 from $24,532,929 at December 31, 2024.
• The company remains dependent on external financing sources to sustain operations and fund growth initiatives, raising substantial doubt about its ability to continue as a going concern.
• Material weaknesses in internal controls over financial reporting were identified, including inadequate supervision, segregation of duties, and ineffective IT general controls.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months due to significant net losses, negative operating cash flows, and dependence on external financing.
• The company may not be successful in executing its plans to expand its product portfolio, distribution channels, or secure necessary funding.
• There is no assurance that the company will be able to obtain additional financing on acceptable terms, or at all, which could adversely affect operations and growth initiatives.
• The terms of any future financing may adversely affect the holdings or rights of existing shareholders.
• The company is subject to risks associated with substantial expenditures for research and development, with no assurance of successful product development, regulatory approval, or commercial viability.
• Supply chain disruptions, including timely supply of materials, services, and products, could adversely impact manufacturing operations and ability to meet customer demand.
• Volatility in the availability and cost of materials or services, including rising prices due to inflation, poses a risk.
• Difficulties or delays in obtaining required import or export approvals could hinder operations.
• Shipment delays due to transportation interruptions or capacity constraints (e.g., reduced air/ground transport, port closures) are a risk.
• Information technology or infrastructure failures, including those of third-party suppliers, could disrupt business.
• Natural disasters or other events beyond control (e.g., earthquakes, epidemics, geopolitical turmoil) could adversely affect operations.
• Hikes in medicine prices and cuts in healthcare spending, particularly in the EU, could impact the sustainability of healthcare systems and the company's business.
• The company faces competition from other products in the same therapeutic categories and potential new products from competitors.
• The company has identified material weaknesses in its internal controls over financial reporting, specifically regarding supervision, segregation of duties, and IT general controls, which could adversely affect its ability to record, process, summarize, and report financial information reliably.

Future Outlook

Management plans to expand its portfolio of brand-name and private-label products, launch new distribution channels, and increase sales from recently secured agreements, such as the exclusive distribution of Sky Premium Life products in the UAE. The company also intends to expand the customer base of its subsidiary, Cosmofarm S.A., and strengthen existing and secure new contract manufacturing agreements for CANA S.A. From a financing perspective, the company is pursuing amendments to debt facilities to defer principal repayments and exploring additional debt financing opportunities. The availability of proceeds from the $300 million senior secured convertible promissory notes, primarily for digital asset acquisition and working capital, is expected to significantly improve liquidity. The company also anticipates increased R&D expenses for the foreseeable future as it develops new patented pharmaceuticals and proprietary nutraceutical products.

Management Comments

• "While the Company’s revenues have grown, they remain insufficient to fund operating expenses and meet debt obligations as they become due."
• "The Company remains dependent on external financing sources to sustain operations and fund growth initiatives."
• "The availability of these proceeds [from the $300M convertible note agreement], primarily intended for digital asset acquisition and working capital, significantly improves the Company’s liquidity and alleviates substantial doubt regarding our ability to continue as a going concern for at least the next 12 months."
• "Management is also considering postponing certain payments to suppliers and other creditors if required."
• "Although these actions are intended to address the going concern uncertainty, there can be no assurance that the Company will be successful in executing its plans or obtaining the necessary funding."
• "The proceeds from the ATM sales provide additional working capital and mitigate, to some extent, the Company’s liquidity constraints."
• "Management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued."
• "Our strategic plan, which strikes a balance between growth and sustainability, emphasizes synergies, vertical integration, operational efficiencies, R&D, brand expansion, and the global growth of our distribution network and facilities."
• "We intend to continue to pursue active ongoing acquisitions."
• "We are committed to serving our customers while continuing to innovate and provide products that make a difference in the lives of individuals."
• "We strive to maximize our shareholders value by adapting to market realities and customer needs."
• "We believe the foregoing efforts will effectively remediate the identified material weakness in internal controls over financial reporting."

Industry Context

Cosmos Health operates in the international healthcare group, encompassing nutraceuticals, pharmaceuticals, and healthcare distribution. The industry is characterized by increasing demand for nutraceutical products globally, high growth opportunities, and a focus on R&D for novel products. However, it also faces challenges such as supply chain disruptions, rising medicine prices, and healthcare spending cuts, particularly in European markets. The company's strategic focus on vertical integration, contract manufacturing, and digital platforms (like Cloudscreen for drug repurposing) aligns with broader industry trends towards efficiency, innovation, and diversified revenue streams. Its expansion into the UAE for nutraceuticals indicates a pursuit of high-growth emerging markets.

Comparison to Industry Standards

• The company's gross profit margin improvement, driven by a shift towards higher-margin nutraceuticals and contract manufacturing, suggests a positive trend in product mix optimization, which is a common strategy for pharmaceutical companies seeking to enhance profitability.
• The acquisition of Cloudscreen, an AI-powered platform for drug repurposing, positions Cosmos Health in line with the growing industry trend of leveraging artificial intelligence for R&D efficiency and innovation, similar to larger pharmaceutical players investing in AI-driven drug discovery.
• The company's dependence on external financing and significant accumulated deficit, despite revenue growth, indicates a financial profile that may be weaker than established, profitable industry peers, particularly those with mature product pipelines and stable cash flows.
• The identified material weaknesses in internal controls over financial reporting are a concern and fall below the robust governance standards expected of publicly traded companies in the healthcare sector, which typically require stringent compliance and operational integrity.
• The expansion of distribution networks and contract manufacturing agreements, particularly with entities like AstraZeneca, Merck, Unilever, and Procter & Gamble through Cana, demonstrates an ability to engage with industry giants, suggesting a level of operational capability comparable to regional leaders in the pharmaceutical manufacturing and distribution space.

Management Changes

Corporate Governance

Legal Proceedings

• A payment request was issued by the Greek court in relation to a fine arising from a tax audit of Cosmofarm for the financial year 2014. The company settled additional taxes and fines of $99,644 but has filed a claim to recover the amount through appeal, which remains pending.
• A criminal case involving dishonored checks issued by Cosmofarm's customer, Kafantaris, resulted in a conviction (Decision No. 1599/2024) on January 26, 2024.
• The company's appeal against Eleutheria Drakopoulou and Decision No. 1389/2021 was granted in part, with the case settled in two equal installments of $37,880 and $37,993 by Cosmofarm SA on July 31, 2024, and October 31, 2024, respectively.
• Cana Laboratories S.A. has two pending lawsuits against Evangelismos Hospital for unpaid invoices totaling EUR 526,436. A hearing for one was postponed from December 11, 2024, and the second is scheduled for December 9, 2025. Collection is considered highly probable.
• A lawsuit against Papanikolaou Hospital for EUR 89,300 was resolved through an out-of-court settlement, with the company awarded EUR 89,948, collected in October 2025.
• An employment dispute with a former Cana Laboratories employee was settled on April 28, 2025, with the company agreeing to pay EUR 62,500 ($83,719) in nine installments, which were made as of September 30, 2025.
• A lease dispute against Cana for restitution of a leased property and monetary claims has seen monetary claims settled, but the claim for restitution remains pending and is expected to be accepted.
• Cosmofarm SA is initiating legal action to recover approximately EUR 20,301 in unpaid invoices from one customer, with the hearing expected in 2026, and is preparing two further lawsuits for EUR 15,143 and EUR 15,255 from two other customers, with hearings also expected in 2026, all with anticipated favorable outcomes.

Related Party Transactions

• Doc Pharma S.A. (CEO's son is CEO): The company had a prepaid balance of $3,993,654 and accounts payable of $419,314 as of September 30, 2025. It also had a receivable balance of $2,819,563 (with a $1.6 million allowance for doubtful accounts). Purchases from Doc Pharma were $1,052,836 and sales were $958,582 for the nine months ended September 30, 2025. Agreements include a CMO agreement, R&D agreement, and a royalty-bearing exclusive worldwide license for cancer treatment patents.
• Panagiotis Kozaris (former General operational manager and current employee of Cosmofarm S.A.): The company had a prepaid balance of $194,215 for shares as of September 30, 2025.
• Basotho Investment Limited (Panagiotis Kozaris is a director): The company issued 120,000 shares of common stock for services rendered on November 21, 2023.
• Maria Kozari (daughter of Panagiotis Kozaris, owner of Pharmacy & More): The company had an outstanding receivable balance of $1,283,131 (with a $907,175 allowance for doubtful accounts) as of September 30, 2025. The company plans to acquire Pharmacy & More in fiscal year 2025.
• Grigorios Siokas (CEO): The company had a prepaid balance of $397,406 relating to prepaid salaries. Outstanding loans payable from Grigorios Siokas were $0 as of September 30, 2025. The company settled $1,434,978 in outstanding obligations (salaries and performance-related bonuses) by issuing 3,096,954 shares of common stock between January 13, 2025, and May 23, 2025.
• George Terzis (CFO): The company had a balance of $190,000 relating to unpaid salaries and bonuses.
• Nikolaos Bardakis (COO): The company had a balance of $15,384 relating to unpaid bonuses.
• Dimitrios Goulielmos (former CEO and Director): The company had a non-interest bearing, no-maturity date notes payable balance of $11,970 as of September 30, 2025.

Stakeholder Impact

• Shareholders: Potential dilution from ongoing equity issuances (ATM program, convertible notes) and warrant exercises. The 'going concern' warning and material weaknesses in internal controls pose significant risks to shareholder value, despite recent Nasdaq compliance. The increase in net loss impacts earnings per share negatively.
• Employees: Recruitment of additional management and scientific personnel at Cana and new employees at Cosmofarm indicates job growth and stability in these segments. However, the overall financial instability and potential cost-cutting measures could create uncertainty.
• Customers: Expansion of product portfolio, distribution channels, and contract manufacturing agreements aims to provide a broader range of products and improved service. Integration of Bikas into Cosmofarm's robotic systems is expected to elevate service levels.
• Suppliers/Creditors: Management is considering postponing certain payments to suppliers and other creditors, which could negatively impact these stakeholders. The company's dependence on external financing to meet debt obligations highlights potential payment risks.
• Regulatory Authorities: The company's efforts to remediate material weaknesses in internal controls and regain Nasdaq compliance demonstrate a commitment to regulatory adherence, which is positive for maintaining trust and market access.

Next Steps

• Expand the portfolio of brand-name and private-label products.
• Launch new distribution channels and increase sales from recently secured agreements (e.g., Sky Premium Life in UAE).
• Expand the customer base of Cosmofarm S.A. to substantially increase wholesale revenue.
• Strengthen existing contract manufacturing agreements and secure new ones for CANA S.A.
• Pursue amendments to certain debt facilities to defer principal repayments.
• Explore additional debt financing opportunities to enhance liquidity.
• Work towards the effectiveness of the registration statement covering shares issuable upon conversion of the Initial Note to receive an additional $2 million.
• Consider postponing certain payments to suppliers and other creditors if required.
• Continue to execute on the core elements of the Growth Strategy, including high-margin segments, generic pharmaceuticals, manufacturing, global networks, corporate reorganization, and innovation.
• Remediate material weaknesses in internal controls by December 31, 2025, by engaging a third-party consultant, updating the organizational chart, reallocating roles, expanding the finance team, and implementing training programs.
• Initiate legal action to recover approximately $20,301, $15,143, and $15,255 in unpaid invoices from customers through Cosmofarm SA, with hearings expected in 2026.
• Present relevant supporting invoices at the new hearing for the lawsuit against Evangelismos Hospital (date not yet set).
• Acquire Pharmacy & More within fiscal year 2025 and make it the first shop-in-shop for Sky Premium Life products.

Key Dates

Recommendation

Cosmos Health Inc. exhibits strong top-line revenue growth and strategic expansion into new markets and product lines, including AI-driven drug repurposing and nutraceuticals. The significant increase in cash and restricted cash from recent financing activities, including a substantial convertible note agreement and ATM sales, has temporarily alleviated immediate liquidity concerns and helped regain Nasdaq compliance. However, the company continues to report substantial net losses, primarily driven by non-cash charges related to new financing instruments, and remains cash flow negative from operations. The explicit 'going concern' warning, coupled with identified material weaknesses in internal controls and a high volume of related-party transactions with significant allowances for doubtful accounts, introduces considerable risk. While the growth trajectory is promising, the path to sustained profitability and operational stability is still uncertain and heavily reliant on future financing. A 'hold' recommendation is appropriate, acknowledging the growth potential while emphasizing the significant financial and operational risks that warrant close monitoring before a more definitive stance can be taken.

Keywords

Healthcare, Pharmaceuticals, Nutraceuticals, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Going Concern, Capital Raise, Convertible Notes, ATM Program, Digital Assets, Ethereum, Contract Manufacturing, Distribution Network, Sky Premium Life, Cana S.A., Cosmofarm S.A., Cloudscreen, AI Platform, Drug Repurposing, Nasdaq Compliance, Internal Controls, Related Party Transactions